Abstract

This task order is designed to determine the relative effectiveness (as cancer chemopreventive agents) of EGFr, MEK, and PI3K inhibitors administered on various schedules. This information will be used as a guide in designing clinical trials of these agents.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Station Support Contracts (N03)
Project #
261201200013I-0-26100007-2
Application #
8744466
Study Section
Project Start
2013-09-19
Project End
2015-09-18
Budget Start
Budget End
Support Year
Fiscal Year
2013
Total Cost
$647,739
Indirect Cost